Ben A van Hout|James W Shaw - JoVE Visualize

Showing results (1-10 of 77) with videos related to

Pageof 8

Sort By:

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021

Mapping EQ-5D-3L to EQ-5D-5LBen A van Hout, James W Shaw

Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 9, 2014

Assessing uncertainties surrounding combined endpoints for use in economic modelsBart M Heeg, Ben A van Hout

Pharmacoeconomics|January 19, 2006

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in GermanyGerd Laux, Bart Heeg, Ben A van Hout, et al.

Health Economics|January 29, 2005

Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertaintyMaiwenn J Al, Talitha L Feenstra, Ben A van Hout

Pharmacoeconomics|January 19, 2006

Modelling the impact of compliance on the costs and effects of long-acting risperidone in CanadaP S Chue, Bart Heeg, Erik Buskens, et al.

Pharmacoeconomics|March 12, 2003

The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximationBen A van Hout, Dennis D Gagnon, Pauline McNulty, et al.

BMJ Open|June 11, 2015

Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the diseaseStephanie Stephens, Marc F Botteman, Mary A Cifaldi, et al.

Journal of Managed Care & Specialty Pharmacy|May 24, 2017

The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision MakingA Reginald Waldeck, Marc F Botteman, Richard E White, et al.

Critical Care (London, England)|August 18, 2004

Prevalence and incidence of severe sepsis in Dutch intensive care unitsAukje van Gestel, Jan Bakker, Christiaan P W M Veraart, et al.

Applied Health Economics and Health Policy|June 29, 2010

Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulationsJ Floris S Logman, Bart M S Heeg, Johan Herlitz, et al.

Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:

Pageof 8

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021

Mapping EQ-5D-3L to EQ-5D-5LBen A van Hout, James W Shaw

Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 9, 2014

Assessing uncertainties surrounding combined endpoints for use in economic modelsBart M Heeg, Ben A van Hout

Pharmacoeconomics|January 19, 2006

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in GermanyGerd Laux, Bart Heeg, Ben A van Hout, et al.

Health Economics|January 29, 2005

Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertaintyMaiwenn J Al, Talitha L Feenstra, Ben A van Hout

Pharmacoeconomics|January 19, 2006

Modelling the impact of compliance on the costs and effects of long-acting risperidone in CanadaP S Chue, Bart Heeg, Erik Buskens, et al.

Pharmacoeconomics|March 12, 2003

The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximationBen A van Hout, Dennis D Gagnon, Pauline McNulty, et al.

BMJ Open|June 11, 2015

Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the diseaseStephanie Stephens, Marc F Botteman, Mary A Cifaldi, et al.

Journal of Managed Care & Specialty Pharmacy|May 24, 2017

The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision MakingA Reginald Waldeck, Marc F Botteman, Richard E White, et al.

Critical Care (London, England)|August 18, 2004

Prevalence and incidence of severe sepsis in Dutch intensive care unitsAukje van Gestel, Jan Bakker, Christiaan P W M Veraart, et al.

Applied Health Economics and Health Policy|June 29, 2010

Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulationsJ Floris S Logman, Bart M S Heeg, Johan Herlitz, et al.

Pageof 8